Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch
10:00am, Wednesday, 24'th Feb 2021
Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related d
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020
What's in the Cards for Sarepta (SRPT) This Earnings Season?
09:51am, Tuesday, 16'th Feb 2021
Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
09:39pm, Monday, 15'th Feb 2021
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
12:37pm, Thursday, 11'th Feb 2021
New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such
Los Angeles, California--(Newsfile Corp. - February 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of S
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
11:18pm, Saturday, 06'th Feb 2021
New York, New York--(Newsfile Corp. - February 6, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such in
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:11pm, Thursday, 04'th Feb 2021
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
04:30pm, Thursday, 04'th Feb 2021
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the four winners of the Rare
LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics,
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 29'th Jan 2021
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that
After A 50% Fall Sarepta Therapeutics Stock Now Looks Attractive
10:40am, Friday, 22'nd Jan 2021
Sarepta Therapeutics stock, is a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases. SRPT stock is now at the sam
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
11:17am, Thursday, 21'st Jan 2021
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
Sarepta (SRPT) Inks New Gene Editing Research Collaboration
11:17am, Thursday, 14'th Jan 2021
Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
08:30am, Wednesday, 13'th Jan 2021
-- Alliance will assess the use of Sarepta's proprietary gene editing technology and Genevant's proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for a
